Umbrella Protocol for Phase I/IIa Trials of Molecularly Matched Targeted Therapies Plus Radiotherapy in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation: NCT Neuro Master Match - N²M² (NOA-20)
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Alectinib (Primary) ; Asunercept (Primary) ; Atezolizumab (Primary) ; Idasanutlin (Primary) ; Palbociclib (Primary) ; Temsirolimus (Primary) ; Vismodegib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms N2M2; N2M2/NOA-20
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 26 Sep 2023 Status changed from recruiting to completed.
- 26 Sep 2023 Status changed from recruiting to completed.